Screening of Specific Inhibitors for Human Carboxylesterases or Arylacetamide Deacetylase

Esterases catalyze the hydrolysis of therapeutic drugs containing esters or amides in their structures. Human carboxylesterase (CES) and arylacetamide deacetylase (AADAC) are the major enzymes that catalyze the hydrolysis of drugs in the liver. Characterization of the enzyme(s) responsible for drug metabolism is required in drug development and to realize optimal drug therapy. Because multiple enzymes may show a metabolic potency for a given compound, inhibition studies using chemical inhibitors are useful tools to determine the contribution of each enzyme in human tissue preparations. The purpose of this study was to find specific inhibitors for human CES1, CES2, and AADAC. We screened 542 chemicals for the inhibition potency toward hydrolase activities of p-nitrophenyl acetate by recombinant CES1, CES2, and AADAC. We found that digitonin and telmisartan specifically inhibited CES1 and CES2 enzyme activity, respectively. Vinblastine potently inhibited both AADAC and CES2, but no specific inhibitor of AADAC was found. The inhibitory potency and specificity of these compounds were also evaluated by monitoring the effects on hydrolase activity of probe compounds of each enzyme (CES1: lidocaine, CES2: CPT-11, AADAC: phenacetin) in human liver microsomes. Telmisartan and vinblastine strongly inhibited the hydrolysis of CPT-11 and/or phenacetin, but digitonin did not strongly inhibit the hydrolysis of lidocaine, indicating that the inhibitory potency of digitonin was different between recombinant CES1 and liver microsomes. Although we could not find a specific inhibitor of AADAC, the combined use of telmisartan and vinblastine could predict the responsibility of human AADAC to drug hydrolysis.

[1]  D. Murry,et al.  Hydrolysis of Capecitabine to 5′-Deoxy-5-fluorocytidine by Human Carboxylesterases and Inhibition by Loperamide , 2005, Journal of Pharmacology and Experimental Therapeutics.

[2]  Elizabeth I. Parkinson,et al.  Requirements for mammalian carboxylesterase inhibition by substituted ethane-1,2-diones. , 2011, Bioorganic & medicinal chemistry.

[3]  A. Miyashita,et al.  Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective β3-adrenoceptor agonist , 2012, Xenobiotica; the fate of foreign compounds in biological systems.

[4]  C. Kuo,et al.  Calcium binding by human and rabbit serum paraoxonases. Structural stability and enzymatic activity. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[5]  K. Krisch,et al.  [Phosphoric acid-bis-(p-nitro-phenylester), a new inhibitor of microsomal carboxylesterases]. , 1967, Hoppe-Seyler's Zeitschrift fur physiologische Chemie.

[6]  Y. Kobayashi,et al.  A Novel Polymorphic Allele of Human Arylacetamide Deacetylase Leads to Decreased Enzyme Activity , 2012, Drug Metabolism and Disposition.

[7]  L. Maltais,et al.  Recommended nomenclature for five mammalian carboxylesterase gene families: human, mouse, and rat genes and proteins , 2010, Mammalian Genome.

[8]  E. T. Williams,et al.  Characterization of Recombinant Human Carboxylesterases: Fluorescein Diacetate as a Probe Substrate for Human Carboxylesterase 2 , 2011, Drug Metabolism and Disposition.

[9]  T. Fukami,et al.  Prilocaine- and Lidocaine-Induced Methemoglobinemia Is Caused by Human Carboxylesterase-, CYP2E1-, and CYP3A4-Mediated Metabolic Activation , 2013, Drug Metabolism and Disposition.

[10]  Bruce D. Hammock,et al.  Analysis of Mammalian Carboxylesterase Inhibition by Trifluoromethylketone-Containing Compounds , 2007, Molecular Pharmacology.

[11]  Y. Kobayashi,et al.  Arylacetamide Deacetylase Is a Determinant Enzyme for the Difference in Hydrolase Activities of Phenacetin and Acetaminophen , 2010, Drug Metabolism and Disposition.

[12]  M. Dolan,et al.  Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. , 2000, Cancer research.

[13]  Yuichiro Sato,et al.  Simultaneous Absolute Protein Quantification of Carboxylesterases 1 and 2 in Human Liver Tissue Fractions using Liquid Chromatography-Tandem Mass Spectrometry , 2012, Drug Metabolism and Disposition.

[14]  A. Odermatt,et al.  Appropriate Function of 11β-Hydroxysteroid Dehydrogenase Type 1 in the Endoplasmic Reticulum Lumen Is Dependent on Its N-terminal Region Sharing Similar Topological Determinants with 50-kDa Esterase* , 2004, Journal of Biological Chemistry.

[15]  T. Satoh,et al.  Interindividual variation in carboxylesterase levels in human liver microsomes. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[16]  O. Lockridge,et al.  Tissue distribution of human acetylcholinesterase and butyrylcholinesterase messenger RNA. , 1994, Toxicon : official journal of the International Society on Toxinology.

[17]  T. Fukami,et al.  Human Arylacetamide Deacetylase Is a Principal Enzyme in Flutamide Hydrolysis , 2009, Drug Metabolism and Disposition.

[18]  F. Gil,et al.  Human liver paraoxonase (PON1): Subcellular distribution and characterization , 1998, Journal of biochemical and molecular toxicology.

[19]  K. Iwatsubo.  STUDIES ON THE CLASSIFICATION OF THE ENZYMES HYDRO-LYZING ESTER-FORM DRUGS IN LIVER MICROSOMES , 1965 .

[20]  P. Beroza,et al.  Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. , 2005, Journal of medicinal chemistry.

[21]  Kazuya Maeda,et al.  PREDOMINANT CONTRIBUTION OF OATP1B3 TO THE HEPATIC UPTAKE OF TELMISARTAN, AN ANGIOTENSIN II RECEPTOR ANTAGONIST, IN HUMANS , 2006, Drug Metabolism and Disposition.

[22]  K. Tetsuka,et al.  Quantitative Prediction of Human Intestinal Glucuronidation Effects on Intestinal Availability of UDP-Glucuronosyltransferase Substrates Using In Vitro Data , 2012, Drug Metabolism and Disposition.

[23]  S. Reddy,et al.  Paraoxonase-2 Is a Ubiquitously Expressed Protein with Antioxidant Properties and Is Capable of Preventing Cell-mediated Oxidative Modification of Low Density Lipoprotein* , 2001, The Journal of Biological Chemistry.

[24]  P. Beroza,et al.  Discovery of novel selective inhibitors of human intestinal carboxylesterase for the amelioration of irinotecan-induced diarrhea: synthesis, quantitative structure-activity relationship analysis, and biological activity. , 2004, Molecular pharmacology.

[25]  C. Pope,et al.  Carboxylesterase and A-esterase activities during maturation and aging: relationship to the toxicity of chlorpyrifos and parathion in rats. , 2000, Toxicological sciences : an official journal of the Society of Toxicology.

[26]  Kayoko Ohura,et al.  Distinct Patterns of Aging Effects on the Expression and Activity of Carboxylesterases in Rat Liver and Intestine , 2014, Drug Metabolism and Disposition.

[27]  Y. Kobayashi,et al.  Contributions of Arylacetamide Deacetylase and Carboxylesterase 2 to Flutamide Hydrolysis in Human Liver , 2012, Drug Metabolism and Disposition.

[28]  R. Benjamin,et al.  Concentrations of vinblastine in human intracerebral tumor and other tissues , 2004, Journal of Neuro-Oncology.

[29]  S. Tokudome,et al.  IDENTIFICATION OF THE CYTOSOLIC CARBOXYLESTERASE CATALYZING THE 5′-DEOXY-5-FLUOROCYTIDINE FORMATION FROM CAPECITABINE IN HUMAN LIVER , 2004, Drug Metabolism and Disposition.

[30]  B. Yan,et al.  Human and rodent carboxylesterases: immunorelatedness, overlapping substrate specificity, differential sensitivity to serine enzyme inhibitors, and tumor-related expression. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[31]  T. Saitoh,et al.  Different Inhibitory Effects in Rat and Human Carboxylesterases , 2009, Drug Metabolism and Disposition.

[32]  H. McLeod,et al.  Structure and characterization of human carboxylesterase 1A1, 1A2, and 1A3 genes , 2008, Pharmacogenetics and genomics.

[33]  Y. Kobayashi,et al.  Metabolic activation by human arylacetamide deacetylase, CYP2E1, and CYP1A2 causes phenacetin-induced methemoglobinemia. , 2012, Biochemical pharmacology.

[34]  Peter Kuhn,et al.  Multisite promiscuity in the processing of endogenous substrates by human carboxylesterase 1. , 2006, Journal of molecular biology.

[35]  T. Fukami,et al.  The emerging role of human esterases. , 2012, Drug metabolism and pharmacokinetics.

[36]  Shiori Takahashi,et al.  In Vitro Evaluation of Inhibitory Effects of Antidiabetic and Antihyperlipidemic Drugs on Human Carboxylesterase Activities , 2010, Drug Metabolism and Disposition.

[37]  S. Yamaori,et al.  Involvement of human blood arylesterases and liver microsomal carboxylesterases in nafamostat hydrolysis. , 2006, Drug metabolism and pharmacokinetics.

[38]  H. McLeod,et al.  Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  Zhang Chengliang,et al.  Evaluation of the inhibitory effects of antihypertensive drugs on human carboxylesterase in vitro. , 2013, Drug metabolism and pharmacokinetics.

[40]  R. Benjamin,et al.  Concentration of vinblastine in human intracerebral tumor and other tissues. , 1983, Journal of neuro-oncology.

[41]  J. Chang,et al.  A potent and selective inhibitor of KIAA1363/AADACL1 that impairs prostate cancer pathogenesis. , 2011, Chemistry & biology.

[42]  Y. Kobayashi,et al.  Human arylacetamide deacetylase is responsible for deacetylation of rifamycins: rifampicin, rifabutin, and rifapentine. , 2011, Biochemical pharmacology.